|
Management of Myelomeningocele Study (MOMS) Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Management of Myelomeningocele Study (MOMS) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Management of Myelomeningocele Study (MOMS) Clinical research trials and Management of Myelomeningocele Study (MOMS) health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Management of Myelomeningocele Study (MOMS). Management of Myelomeningocele Study (MOMS) Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Management of Myelomeningocele Study (MOMS) clinical trial. Human subjects frequently get the finest healthcare available for their Management of Myelomeningocele Study (MOMS) condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Management of Myelomeningocele Study (MOMS)  Management of Myelomeningocele Study (MOMS)
Management of Myelomeningocele Study (MOMS)
For Condition: Spinal Dysraphism,Meningomyelocele
Status: Recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) ,
Synopsis: Spina bifida (myelomeningocele) is a complex birth defect in which a portion of the spinal cord is not fully developed. The overlying bones and skin are incompletely formed and the underdeveloped area of the spinal cord is exposed on the surface of the back. Spina bifida defects are closed soon after birth to prevent further damage to the spinal cord and nerves. The Management of Myelomeningocele Study (MOMS) is a research study comparing two approaches to the treatment of babies with spina bifida: surgery before birth (prenatal surgery) and the standard closure, surgery after birth (postnatal surgery)
Details: Since 1997, more than 200 fetuses have had in utero closure of myelomeningocele by open maternal-fetal surgery. Preliminary clinical evidence suggests that this procedure reduces the incidence of shunt-dependent hydrocephalus and restores the cerebellum and brainstem to more normal configuration. However, clinical results of prenatal surgery for myelomeningocele are based on comparisons with historical controls and examine only efficacy, not safety. MOMS will determine if intrauterine repair of fetal myelomeningocele at 19 to 25 weeks of gestation improves outcomes as compared to standard postnatal repair. Outcomes assessed include death, the need for ventricular decompressive shunting by one year of life and neurologic function at 30 months of age. Two hundred women, whose fetuses have spina bifida, will be enrolled in the study and randomized to have either prenatal surgery or postnatal surgery. After a central screening process which includes a medical record review, all women will have an extensive baseline evaluation that will include ultrasound, MRI, physical exam, social work evaluation, psychological screening, and education about spina bifida and prenatal surgery. For women who are eligible following the central screening process, all screening, surgery and follow-up visits will be performed at one of three MOMS Centers. The mother, if eligible, and her support person will travel (at the expense of the study) to the MOMS Center for screening and randomization. Women assigned to have prenatal surgery will be scheduled for surgery within 1 to 3 days after they are randomized. They will stay near the MOMS Center until they deliver. Women in the postnatal group will travel back to their assigned MOMS Center to deliver. Both groups will deliver their babies by C-section around the 37th week of their pregnancies. Babies born to women in the postnatal surgery group will have their spina bifida defects closed when they are medically stable, usually within 48 hours of birth. Children and their parents will return to their assigned MOMS Center at 1 year and 2 ½ years of age for follow-up evaluation. Motor function, developmental progress, and bladder, kidney, and brain development will be assessed.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Pregnant women carrying a fetus diagnosed with myelomeningocele - Myelomeningocele lesion that starts no higher than T1 and no lower than S1 with hindbrain herniation present - Gestational age at randomization of 19 weeks 0 days to 25 weeks 6 days - Normal karyotype - Singleton pregnancy - United States resident - Able to travel to study site for study evaluation, procedures, and visits (if randomized to prenatal surgery, must stay near center until delivery) - Support person to travel and stay with participant Exclusion Criteria - Maternal insulin-dependent pregestational diabetes - Short or incompetent cervix or cervical cerclage - Placenta previa - Body mass index of 35 or more - Previous spontaneous delivery prior to 37 weeks - Maternal HIV, Hepatitis-B or Hepatitis-C status positive - Uterine anomaly - Maternal medical condition which is a contraindication to surgery or general anesthesia - Other fetal anomaly
Total Enrollment: 200
Location and Contact Information:
Overall Study Official:
NancyChescheir, Study Director, National Institute of Child Health and Human Development (NICHD)
The Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19104
United States
Recruiting Scott Adzick
University of California at San Francisco *Recruiting*
San Francisco, California, 94143
United States
Recruiting Michael Harrison
Vanderbilt University Medical Center *Recruiting*
Nashville, Tennessee, 37232
United States
Recruiting Joe Bruner
Additional Information:
Study ID Numbers: U01HD41665; U01HD41669,U01HD41667,U01HD41666
Study Start Date: February 2003
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00060606
Other Meningomyelocele Studies:
1. Management of Myelomeningocele Study (MOMS)
Related Studies:
Other Meningomyelocele Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials
Management of Myelomeningocele Study (MOMS)
|
|
|
|
|
|
|
|
